Secondary hyperparathyroidism (SHPT) is common in chronic kidney disease (CKD) and
dialysis patients, and results in renal osteodystrophy, thus causing the decreased synthesis …

The objective of this study was to determine the impact of calcium sensing receptor (CASR)
A990G genetic polymorphism on parathyroid hormone (PTH) lowering response to …

Background Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …

Aims BsmI polymorphism of the vitamin D receptor gene has been linked to
hyperparathyroidism severity and calcitriol levels. The aim of this study was to analyze the …

The present study was performed to investigate the association of calcium-sensing receptor
(CaSR) genotypes with parathyroid hormone (PTH) secretion in hemodialysis patients …

Cinacalcet, a novel calcimimetic compound, is effective in reducing parathyroid hormone
(PTH) levels in approximately 70% of patients with secondary hyperparathyroidism …

Aims: Calcimimetics are effective in reducing parathyroid hormone (PTH) levels in patients
with secondary hyperparathyroidism, but variability in dose response has been noted. We …

Results There were modest associations of CASR SNPs with increased baseline serum
parathyroid hormone and bone alkaline phosphatase primarily with the minor allele in the …

Dialysed patients suffering from chronic kidney disease (CKD) show varied levels of
concentration of parathyroid hormone (PTH) in the blood. One of the factors in charge of …

PURPOSE: Low level of parathyroid hormone (PTH) is a risk factor that might cause hip
fracture in dialysis patients. Low calcium dialysate (LCD) has been suggested as an …